The subject has received bevacizumab for their disease unless in the context of primary therapy for newly diagnosed glioma
Patients with newly diagnosed RMS of any subtype, except adult-type pleomorphic, based upon institutional histopathologic classification, are eligible to enroll on the study based upon stage, group, and age, as below
Enrollment on ANBL00B1 or APEC14B1 is required for all newly diagnosed patients
Group C: patients < 18 months (< 547 days) of age with newly diagnosed INRG stage Ms neuroblastoma/ganglioneuroblastoma
Newly diagnosed patients with histologically proven ALCL (International Classification of Diseases for Oncology [ICD-0] code: 9714/3)
Subject with histologically or cytologically confirmed extensive-stage disease SCLC which is newly diagnosed and chemotherapy naive
Patients with CNS GCTs who are newly diagnosed are excluded from the study
Newly-diagnosed brain cancer with histopathological diagnosis of GBM;
Histologically confirmed newly diagnosed stage I-II HER2/neu positive breast cancer
Newly diagnosed mature B-lineage (CD20 positive) Leukemia/Lymphoma
Be newly diagnosed and previously untreated
Prior WBRT for newly diagnosed brain metastases
Newly diagnosed neuroblastoma or ganglioneuroblastoma as verified by histology and/or demonstration of tumor cells in bone marrow with elevated urinary catecholamine metabolites
Treatment naive for his or her newly diagnosed malignancy for enrollment to groups 1 or 2
newly diagnosed AML unsuitable for intensive chemotherapy
For the Phase II part of the study, newly diagnosed OR refractory/metastatic anaplastic thyroid cancer confirmed by histology, incurable by surgery, radiotherapy or chemoradiotherapy alone or in combination
Newly diagnosed, previously untreated participants with rhabdomyosarcoma (RMS)
Patients with biopsy proven newly diagnosed rhabdomyosarcoma
Have newly diagnosed localized or locally advanced (T1N1-3M0 or T2-3NanyM0), potentially resectable disease without any prior systemic chemotherapy
Group 1: Must have newly diagnosed, pathologically confirmed cHL at Stages IA, IB and IIA without bulky disease. Group 2: Must have newly diagnosed, pathologically confirmed cHL at Stages IIEB, IIIEA,IIIEB, IIIB, IVA and IVB
Elderly (> 60 year old) patients with newly diagnosed AML not eligible for intensive chemotherapy
Newly diagnosed patients who are ineligible or declined to receive intensive chemotherapy after discussion of risks and benefits of that approach or patients with primary refractory/relapsed AML
Newly diagnosed brain cancer or tumor called glioblastoma or GBM
Newly-diagnosed brain cancer or tumor called glioblastoma or GBM
Must have recurrent disease confirmed by MRI (Group 1) or completed SoC therapy such as surgery with adjuvant radiochemotherapy with or without maintenance temozolomide according to local standards for newly diagnosed disease (Group 2)
Patients with newly diagnosed, uncontrolled and or untreated cancer; related central nervous system diseases are excluded.
Newly diagnosed androgen-sensitive metastatic disease; or
Newly diagnosed, treatment naive, HNSCC suitable for surgical resection with planned radiotherapy and/or chemotherapy after surgery
Newly diagnosed histologically proven locoregional OCSCC (T-stage 2-4) without evidence of distant metastases; OCSCC includes the subsites of oral tongue, floor of mouth, gingiva, retromolar trigone, and buccal mucosa
Patients may have metastases, with newly identified peripheral metastases
Newly diagnosed, biopsy proven cancer of the endometrium, prostate or breast
Subjects must be newly diagnosed or suspected to have breast, uterine (endometrial cancer with histologies including endometrioid, serous, clear cell, and carcinosarcoma) or cervical cancer
Histopathologically proven newly-diagnosed primary glioblastoma with complete or partial surgical resection; biopsy not acceptable
Newly diagnosed de novo AML; or
Newly diagnosed (non-M3) AML patients
PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Is currently participating or has participated in any other newly diagnosed therapeutic trial before or after chemoradiation
PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Has known gliomatous meningitis, extracranial disease, or multifocal disease
Documented evidence of newly diagnosed, symptomatic MM, by IMWG criteria within five years of enrollment
Histologically or cytologically confirmed newly diagnosed treatment-naive metastatic adenocarcinoma of the pancreas with metastatic disease diagnosed no more than 8 weeks prior to enrollment
Newly diagnosed or relapsed participants are eligible to participate; this protocol is intended to enroll both previously treated and untreated patients
Patients must have histologically confirmed newly diagnosed or previously untreated (patients may be under no treatment “wait and watch” or have received two cycles of chemotherapy or localized radiation therapy before going on this study) non-Hodgkin’s lymphoma or CLL
Newly diagnosed, histologically confirmed breast cancer
Patients with newly diagnosed AT/RT
Patients with newly diagnosed AT/RT and synchronous extra-CNS MRT
HER-2+ (HER2 status is not required for women diagnosed with DCIS)
Patients with 1?10 newly diagnosed brain metastases deemed to be eligible for radiosurgery\r\n* Prior whole brain radiotherapy (RT) and radiosurgery (to areas outside of the newly diagnosed brain metastases requiring radiosurgery) is allowed
Patient has newly diagnosed disease with no prior therapy
Any prior treatment for the current, newly diagnosed breast cancer
Patients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiforme
Patient must have newly diagnosed, histologically confirmed GBM
Patients with newly diagnosed stage I and II nasal NK cell lymphoma
Four or more newly-diagnosed lesions
In the phase II portion, patients must be newly diagnosed or treatment naive, or have been off adjuvant imatinib therapy for at least 3 months; patients with newly diagnosed GIST and who had been on imatinib for up to 4 weeks prior to signing the consent are allowed to enroll in order to expedite accrual
Newly diagnosed MCL: Confirmed diagnosis of MCL with CD20 and cyclin D1 positivity in tissue\r\nbiopsy; patients must have never received any prior therapy for their disease
Newly diagnosed MCL: Ki67 protein (Ki67) < 50%
Newly diagnosed MCL: Patients must be willing to receive transfusions of blood products
Newly diagnosed MCL: The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patient’s health and survival, than of the MCL, within the subsequent 6 months at the time of consent
Newly diagnosed MCL: Prior treatment with ibrutinib
Newly diagnosed MCL: Patients with blastoid and pleomorphic variants
Newly diagnosed MCL: Ki-67 to be equal or more than 50%
Newly diagnosed MCL: Central nervous system lymphoma
Patients with newly diagnosed brain metastases are eligible as long as they are not planned for WBRT upfront
Cohort A: newly diagnosed AML, no prior cytotoxic chemotherapy
Untreated, non-transplant eligible, newly diagnosed mantle cell lymphoma with measurable disease as determined by computed tomography (CT), and bone marrow biopsy
Elderly subjects (? 65 years) with newly diagnosed AML must be treatment naive and unfit for intensive chemotherapy.
Patients with ICGCTs who are newly diagnosed are excluded from the study
Newly diagnosed disease
Has a newly diagnosed tumor and a curative treatment option or approved therapy is available
newly diagnosed untreated AML in patients ? 65 years of age, if they are not candidates for standard available induction chemotherapy
Subjects with (newly diagnosed or recurrent) metastatic cancer for whom surgery, radiation, or radiosurgery has not been advised by the treating physician.
Newly diagnosed DIPG patients\r\n* Patients must have not received any prior therapy for treatment of their current CNS malignancy other than radiation therapy
PART 2 PATIENTS (NEWLY DIAGNOSED GBM)
Patients should be newly diagnosed HNSCC, with no prior therapy for this disease
Patients with newly diagnosed GCT
newly diagnosed advanced breast cancer, then relapsed with documented evidence of progression while on or after only one line of endocrine therapy
Subjects ? 60 years of age with newly diagnosed AML
Newly diagnosed, histologically confirmed de novo AML (bone marrow blasts ? 20%), or
Diagnosis of newly diagnosed lymphoblastic lymphoma (patients must have < 25% tumor cells in bone marrow by morphology)
newly diagnosed advanced/metastatic breast cancer, treatment naïve
Patients must either not be a candidate for docetaxel chemotherapy for newly diagnosed metastatic prostate cancer, as determined by their treating oncologist, or have declined this therapy
Diagnosed with PNH
Known newly diagnosed cardiac arrhythmia; patients with an arrhythmia that has been stable for at least 3 months will be allowed to participate
Patients must be newly diagnosed with de novo acute myelogenous leukemia
Patients must be newly diagnosed with histologically-proven hepatoblastoma
Newly diagnosed stage IIIA/B NSCLC, PS 0-1
Patients must not have received any prior treatment for current or newly diagnosed breast cancer
“High-risk SMM” per Mayo Clinic or Spanish PETHEMA (Treatment of Newly Diagnosed Patients with Acute Promyelocytic Leukemia) criteria
Newly diagnosed, biopsy-proven stage 0-II breast cancer
Is newly diagnosed with a curative treatment option available.
INCLUSION CRITERIA FOR NEWLY DIAGNOSED PATIENTS WITH DIPG
EXCLUSION CRITERIA FOR NEWLY DIAGNOSED PATIENTS WITH DIPG
Newly diagnosed elderly AML patients (> 60 years) unfit for intensive chemotherapy with cytarabine and anthracyclines are also eligible to this trial given that no clinically beneficial therapy exists for these patients
Newly diagnosed or uncontrolled cancer-related central nervous system disease
COHORT A: The subject must have newly diagnosed prostate cancer with a metastatic site(s)
Subjects must be newly diagnosed or previously diagnosed with CNL or aCML; all patients must have a bone marrow biopsy completed during the screening or baseline period if one has not been done within 90 days of day 1, cycle one
Patients with newly diagnosed, CD30-positive mature T-cell lymphomas
Patients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiforme
Patients with newly diagnosed PVNS with, at least, one measurable site of disease on MRI.
Pre- and post-menopausal women newly diagnosed with DCIS histologically confirmed on breast core biopsy
Newly diagnosed patients with no prior attempt at curative therapy
Newly diagnosed, previously untreated patients with histologically or molecularly confirmed DSRCT
Tumor: newly diagnosed non-disseminated diffuse intrinsic pontine glioma based on clinical AND radiographic finding
Histopathologically confirmed newly diagnosed glioblastoma multiforme; diagnosis must be made by surgical biopsy or excision
Patients must have 3 or fewer newly diagnosed metastatic lesions in the brain with a complete resection of at least one lesion as determined by the study neuroradiologist
Newly diagnosed, treatment naive CP-CML (Cohort 3)
Newly diagnosed disease
Subjects must have newly diagnosed (within 3 years), previously untreated prostate cancer without concurrent malignancy
Newly diagnosed untreated stage IV and/or recurrent after adjuvant therapy with metastatic disease
Newly diagnosed cGVHD defined by:
Have newly diagnosed or recurrent multi-focal Ta, large Ta, high grade Ta, carcinoma in situ (CIS) or T1 bladder cancer
Newly diagnosed cardiac arrhythmia; patients with an arrhythmia that has been stable for at least 3 months will be allowed to participate
Newly diagnosed patients with unilateral group D retinoblastoma
Patients must have newly diagnosed metastatic disease; note this may include non-measurable chest wall recurrence
Newly diagnosed, previously untreated patients with histologically or molecularly confirmed Ewing sarcoma
Patients must have newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases
Arm B: Patients with CML in AP or BP, either newly diagnosed or failing TKI therapy (i.e., Acute Group patients);
Newly diagnosed patients who have not received prior therapy, with the exception of one short course of emergent chemotherapy in newly presenting patients with neurological compromise per provider decision
Documented evidence of symptomatic MM, either newly diagnosed or relapsed/refractory
Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue.
Have newly diagnosed localized or locally advanced (T1N1-3M0 or T2-4NanyM0), potentially resectable disease without any prior systemic chemotherapy
Patients must have a biopsy proven newly diagnosed locally confined, stage T1a, T2a or T2b prostate cancer
Newly diagnosed cardiac arrhythmia; patients with an arrhythmia that has been stable for at least 6 months will be allowed to participate
Patients with 1-10 newly diagnosed brain metastases
The child must be a newly diagnosed patient with any type of malignant disease who will be or is receiving chemotherapy and/or radiation therapy
Patient must be newly diagnosed or relapsed/progressed with a brain tumor that has not previously been treated with CRT\r\n* Note: COG therapeutic study participation is not required for ACCL10P1 enrollment
Diagnosed with ALL
Individuals who have been diagnosed with lung cancer\r\n* Individuals are eligible regardless of date of diagnosis (newly diagnosed or long-term survivor), pathology type or stage of lung cancer, or history of other cancers
Newly diagnosed prostate cancer (PCa) (within 3-months).
The patient must not have received bevacizumab as an upfront treatment in newly diagnosed glioblastoma.
Patients diagnosed with T-cell Lymphomas.
Are newly diagnosed with prostate cancer
Newly diagnosed solid tumor or lymphoma with histological verification
A newly diagnosed, histologically proven cancer arising from the oral cavity and oropharynx
Newly diagnosed, in need of a new line or therapy, or at a treatment decision making timepoint.
PATIENTS: Newly diagnosed with any stage cancer
Patients who are newly diagnosed with acute leukemia and hospitalized to receive their initial 4 weeks of intensive induction chemotherapy for this disease
Newly diagnosed with stage 2 or higher cervical cancer within the past 6 months
Newly diagnosed with any stage of uterine cancer (both sarcoma and carcinosarcoma) in the past 6 months
Be diagnosed with cancer
Newly diagnosed adult cancer patients from VICC and MMC or a participating caregiver designated by the patient
Patient must be newly diagnosed (i.e., not relapsed) with any malignancy
newly diagnosed with I-III non-metastatic cancer
Newly diagnosed with acute leukemia by pathology report
Spouses of women with diagnosed within the past 8 months with stage III or IV ovarian cancer will be eligible to participate, as will the diagnosed wife/partner
Women who have been newly diagnosed with a first primary, epithelial ovarian cancer, have undergone surgical debulking and who will be treatment according to the Armstrong method
Newly diagnosed, primary, epithelial ovarian cancer
Newly diagnosed breast cancer patients
Patient must be a newly diagnosed ALL, in first remission
All patients with newly diagnosed lymphoma
Diagnosed with osteoporosis
Newly diagnosed stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a > 2 year life expectancy
Men newly diagnosed with prostate cancer who are scheduled for prostatectomy (stage T1 or T2)
Newly diagnosed tumors: patients with newly diagnosed grade IV glioma who have had not been previously treated with cranial radiation therapy
Be diagnosed with an adnexal mass
Newly diagnosed breast cancer patients
Newly diagnosed primary brain tumor of any location and any histology (Cohort 1)
Patients must have histologically or cytologically proven advanced non-squamous NSCLC; patients may have newly diagnosed recurrent progressive or refractory disease which may be localized or wide spread
Patients with histologically confirmed malignancy (local or metastatic, newly diagnosed or recurrent disease)
Diagnosed with hypotonia
An adult patient with a newly diagnosed, untreated primary lung cancer diameter 7 mm or more; AND
Have one of the following disease histories: \r\n* Newly-diagnosed or recurrent (local, regional, metastatic) malignant melanoma or breast cancer patients in whom SLN mapping is indicated \r\n** Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas \r\n** Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region\r\n** Newly-diagnosed patients with previous excisional biopsy OR \r\n** Newly-diagnosed gynecologic cancer patients in whom SLN mapping and surgical excision is indicated
Newly diagnosed, untreated mass in posterior fossa, either benign or malignant
Newly-diagnosed or recurrent (local, regional, metastatic) metastatic melanoma or malignant brain tumor patients with:\r\n* Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas, or malignant brain tumor\r\n* Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region\r\n* Newly diagnosed patients with previous excisional biopsy
Newly diagnosed with esophageal cancer.
Patient is diagnosed with cancer
Be diagnosed with T1 or greater LABC, any N and M0.
Patients with newly diagnosed and untreated stage II and II breast cancer scheduled to undergo neoadjuvant chemotherapy
Patients who will be undergoing surgery for newly-diagnosed glioblastoma
Women must have newly diagnosed histologically or cytologically confirmed endometrial cancer
Have newly diagnosed infiltrating ductal carcinoma of the breast
All cancer types and both newly diagnosed and previously treated patients will be included
Newly diagnosed with clinically node-negative breast cancer or melanoma being staged with SLN biopsy
Hospitalized for newly diagnosed acute leukemia
Be diagnosed with a neurodegenerative disease
Providing surgical treatment for newly diagnosed breast cancer patients
PHASE II: Women newly diagnosed with breast cancer on the day they meet with their surgeon for their initial consultation after the visit
Newly diagnosed breast cancer
Patients newly diagnosed with cancer referred from MGH community health centers in Revere, Chelsea, and Charlestown, or surrounding communities referred to receive cancer treatment at the MGH Cancer Center
Newly diagnosed suspected or proven clinical stage I NSCLC (T1 or T2, N0, M0) with no prior treatment for this disease
Histologically confirmed newly diagnosed G4 MG
Patients must have suspected refractory or relapsed pre-B cell ALL or mixed phenotype acute leukemia (MPAL), or if newly diagnosed, the patient must be 60 years of age or older
Newly diagnosed, de novo or secondary, previously untreated AML
Participants must have progressive, advanced cancer as defined by one of the following:\r\n* Newly diagnosed, untreated advanced disease\r\n* Newly diagnosed, untreated metastatic recurrence of earlier stage disease (previous treatment of early stage disease allowed)\r\n* Clinical determination of progressive disease on previous systemic therapy as evidenced by plan to change treatment; any number of prior therapies are acceptable excluding previous EGFR kinase inhibitors